 |
|
Cognitive Decline in Down Syndrome—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We agree with Margallo-Lana and colleagues that the measurement of cognitive decline in DS is difficult, and for that reason our study used a validated dementia scale. Our control group was closely matched to the treated group in regard to age, sex, concomitant medical problems, and pharmacological therapy. In addition, because the diagnosis of early-stage dementia in DS is particularly difficult, we insisted that both controls and treated patients meet the criteria for middle-stage dementia before being enrolled in the study. We also showed that the rate of decline in cognitive performance prior to the institution of donepezil treatment did not differ in the treated group vs the control group.
We cannot comment on the observations by Margallo-Lana and colleagues that improvements in cognitive function in DS may occur without treatment; they provide no details of the neuropsychological measures used to support this claim. Without standard deviations and . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Cognitive Decline in Down Syndrome
Maria Luisa Margallo-Lana, Clive Ballard, Chris Morris, David Kay, Stephen Tyrer, and Brian Moore
Arch Neurol. 2003;60(7):1024.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Dramatic Improvement in Down Syndrome-Associated Cognitive Impairment with Donepezil
Kondoh et al.
The Annals of Pharmacotherapy 2005;39:563-566.
ABSTRACT
| FULL TEXT
|
